Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRIK1 | P39086 | 2/20 | 0.31 |
| ▸ | GRIA2 | P42262 | 2/20 | 0.31 |
| ▸ | GRIA4 | P48058 | 2/20 | 0.31 |
| ▸ | GRIK3 | Q13003 | 2/20 | 0.31 |
| ▸ | GRIK5 | Q16478 | 2/20 | 0.31 |
| ▸ | GRIA1 | P42261 | 1/20 | 0.31 |
| ▸ | GRIK2 | Q13002 | 1/20 | 0.31 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.31 |
| ▸ | AKR1C3 | P42330 | 1/20 | 0.31 |
| ▸ | TSHR | P16473 | 2/20 | 0.30 |
| ▸ | APEX1 | P27695 | 2/20 | 0.30 |
| ▸ | MEN1 | O00255 | 1/20 | 0.30 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2871424 | 1.00 | GRIK1 (0.31) | GRIK1GRIA2GRIA4GRIK3GRIK5 | |
| SCHEMBL3880960 | 0.82 | ALDH1A1 (0.33) | — | |
| SCHEMBL3880964 | 0.82 | ALDH1A1 (0.33) | — | |
| SCHEMBL28995143 | 0.81 | LMNA (0.30) | — | |
| SCHEMBL30478834 | 0.81 | TSHR (0.36) | TSHR | |
| SCHEMBL74357 | 0.81 | GRIK1 (0.31) | GRIK1GRIA2GRIA4GRIK3GRIK5 | |
| SCHEMBL74358 | 0.81 | GRIK1 (0.31) | GRIK1GRIA2GRIA4GRIK3GRIK5 | |
| SCHEMBL30478836 | 0.80 | TSHR (0.35) | TSHR | |
| SCHEMBL30826555 | 0.79 | SLC22A6 (0.35) | GRIK1GRIA2GRIA4GRIK3GRIK5 | |
| SCHEMBL4929051 | 0.79 | RNPEP (0.38) | GRIK1GRIA2GRIA4GRIK3GRIK5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 146 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12558432-B2 | Biocompatible polymeric drug carriers for delivering active agents | CIS BIOPHARMA AG (CH) | 2026-02-24 | — | — | US | claimed |
| US-20220409737-A1 | BIOCOMPATIBLE POLYMERIC DRUG CARRIERS FOR DELIVERING ACTIVE AGENTS | CIS BIOPHARMA AG (CH) | 2022-12-29 | — | — | US | claimed |
| EP-4051320-A1 | BIOCOMPATIBLE POLYMERIC DRUG CARRIERS FOR DELIVERING ACTIVE AGENTS | CIS Pharma AG (CH) | 2022-09-07 | — | — | EP | claimed |
| CN-114641316-A | Biocompatible polymeric drug carriers for delivery of active agents | CIS制药股份公司 | 2022-06-17 | — | — | CN | claimed |
| WO-2021084087-A1 | BIOCOMPATIBLE POLYMERIC DRUG CARRIERS FOR DELIVERING ACTIVE AGENTS | CIS PHARMA AG (CH) | 2021-05-06 | — | — | WO | claimed |
| EP-3071310-B1 | PROCESS ADDITIVE FORMULATION AND METHOD FOR FOAM REDUCTION AND/OR FOR INCREASING DRAINAGE | KEMIRA OYJ (FI) | 2021-05-05 | — | — | EP | claimed |
| US-9382434-B2 | Actinic radiation-curable inkjet ink and image forming method using same | Konica Minolta, Inc. (JP) | 2016-07-05 | — | — | US | claimed |
| EP-0521453-B1 | Polymeric vehicle for coatings | UNIV NORTH DAKOTA (US) | 1996-06-05 | — | — | EP | claimed |
| EP-0431494-B1 | Filtration media with low protein adsorbability | PALL CORP (US) | 1996-02-07 | — | — | EP | claimed |
| EP-0361814-B1 | Fluid treatment system having low affinity for proteinaceous materials | PALL CORP (US) | 1995-11-15 | — | — | EP | claimed |
| EP-0254799-A1 | (Meth)acrylic ester modified organopolysiloxanes, process for making them and their use as adhesive coating compositions | Th. Goldschmidt AG (DE) | 1988-02-03 | — | — | EP | claimed |
| US-20260055182-A1 | ANTI-L1-CAM ANTIBODIES AND THEIR USES FOR DIAGNOSTIC AND THERAPEUTIC APPLICATIONS | CIS BIOPHARMA AG (CH) | 2026-02-26 | — | — | US | disclosed |
| US-12558432-B2 | Biocompatible polymeric drug carriers for delivering active agents | CIS BIOPHARMA AG (CH) | 2026-02-24 | — | — | US | disclosed |
| EP-4615580-A1 | ANTI-L1-CAM ANTIBODIES AND THEIR USES FOR DIAGNOSTIC AND THERAPEUTIC APPLICATIONS | CIS Biopharma AG (CH) | 2025-09-17 | — | — | EP | disclosed |
| WO-2024100200-A1 | ANTI-L1-CAM ANTIBODIES AND THEIR USES FOR DIAGNOSTIC AND THERAPEUTIC APPLICATIONS | CIS PHARMA AG (CH) | 2024-05-16 | — | — | WO | disclosed |
| US-4046720-A | ACRYLAMIDE MONOMER; CHROMATOGRAPHY | CALIFORNIA INSTITUTE OF TECHNOLOGY (US) | 1977-09-06 | — | — | US | disclosed |
| US-4035316-A | HYDROXY- OR AMINE-SUBSTITUTED ACRYLIC MONOMERS | CALIFORNIA INSTITUTE OF TECHNOLOGY (US) | 1977-07-12 | — | — | US | disclosed |
| US-3993849-A | Metal substrate coated with a thermosetting powder coating composition of an acrylic polymer, a hydroxy functional plasticizer and a blocked polyisocyanate cross-linking agent | E. I. DU PONT DE NEMOURS AND COMPANY (US) | 1976-11-23 | — | — | US | disclosed |
| US-3985632-A | COPOLYMERIZATION OF AN ACRYLIC MONOMER AND A CROSS-LINKING AGENT IN AN AQUEOUS SOLUBLE POLYMER | CALIFORNIA INSTITUTE OF TECHNOLOGY (US) | 1976-10-12 | — | — | US | disclosed |
| US-3957741-A | CROSSLINKED, POROUS, POLYACRYLATE BEADS | CALIFORNIA INSTITUTE OF TECHNOLOGY (US) | 1976-05-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12558432-B2 | Biocompatible polymeric drug carriers for delivering active agents | MSR1, CD47, SLC43A1 | GRIK1 3690/4885GRIA2 2435/4885GRIA4 2995/4885 |
| US-20220409737-A1 | BIOCOMPATIBLE POLYMERIC DRUG CARRIERS FOR DELIVERING ACTIVE AGENTS | CD47, DNPEP, MSR1 | GRIK1 4017/4885GRIA2 2612/4885GRIA4 3206/4885 |
| US-20260055182-A1 | ANTI-L1-CAM ANTIBODIES AND THEIR USES FOR DIAGNOSTIC AND THERAPEUTIC APPLICATIONS | IGSF11, L1CAM, CD74 | GRIK1 2429/4885GRIA2 835/4885GRIA4 1275/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.